The Technical Analyst
ProQR Therapeutics NV [PRQR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ProQR Therapeutics NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.00% €2.02
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 163.25 mill |
| EPS: | -0.370 |
| P/E: | -5.46 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 80.82 mill |
| Avg Daily Volume: | 0.210 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.46 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.93x |
| Company: PE -5.46 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€-0.551 (-127.26%) €-2.57 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
€ 1.848 - 2.19 ( +/- 8.51%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - €2.04
Forecast 2: 16:00 - €2.04
Forecast 3: 16:00 - €2.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €2.02 (1.00% ) |
| Volume | 0.176 mill |
| Avg. Vol. | 0.210 mill |
| % of Avg. Vol | 83.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRQR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Last 10 Buy Signals
Latest Press Releases
2024-04-23 07:00:00 - Press Release
Proqr Nominates Martin Maier, Phd To Board And Announces Annual Meeting Of Shareholders To Be Held May 22, 2024
Leiden, netherlands & cambridge, mass., april 23, 2024 (globe newswire) -- proqr therapeutics nv. (nasdaq: prqr) (proqr), a company dedicated to changing lives through transformative rna therapies based on its proprietary axiomer™ rna editing technology platform, today announced the annual general meeting (agm) of shareholders will take place on wednesday, may 22, 2024 at 1630 cet (10:30am edt) at the offices of allen & overy llp, in amsterdam, the netherlands.
2024-04-22 16:31:00 - Press Release
Proqr Highlights Upcoming Presentations On Axiomer™ Rna Editing At Asgct 27th Annual Meeting
Leiden, netherlands & cambridge, mass., april 22, 2024 (globe newswire) -- proqr therapeutics nv (nasdaq: prqr) (proqr), a company dedicated to changing lives through transformative rna therapies, today announced it will present new preclinical data for its proprietary axiomer™ rna editing technology platform, including the first preclinical data for its ax-0810 pipeline program for cholestatic diseases targeting ntcp at the american society of gene & cell therapy (asgct) annual meeting, may 7-11, 2024, in baltimore, maryland.
2024-04-19 07:00:00 - Press Release
Proqr Achieves Successful Defense Of New Challenge To Its Axiomer™ Ip Portfolio
Leiden, netherlands & cambridge, mass., april 19, 2024 (globe newswire) -- proqr therapeutics n.v. (nasdaq: prqr) (proqr), a company dedicated to changing lives through transformative rna therapies, today announced it has again successfully defended against opposition filed against a key patent for its adar-mediated rna editing platform axiomer™.
2024-03-13 07:00:00 - Press Release
Proqr Announces Year End 2023 Operating And Financial Results
Leiden, netherlands & cambridge, mass., march 13, 2024 (globe newswire) -- proqr therapeutics nv. (nasdaq: prqr) (proqr), a company dedicated to changing lives through transformative rna therapies based on its proprietary axiomer™ rna editing technology platform, today reported its financial and operating results for the year ended december 31, 2023, and provided a business update.
2024-01-19 07:00:00 - Press Release
Proqr Highlights New Platform Data From Presentation On Axiomer™ Rna Editing Technology At Deaminet 2024
Leiden, netherlands & cambridge, mass., jan. 19, 2024 (globe newswire) -- proqr therapeutics nv (nasdaq: prqr) (proqr), a company dedicated to changing lives through transformative rna therapies based on its proprietary axiomer™ rna editing technology platform, today highlighted key updates from its oral presentation at the 5th international conference on base editing, prime editing & related enzymes (deaminet 2024) in san diego, california.
Latest News
2023-12-28 09:46:06 - Zacks Investment Research
Is ProQR (PRQR) Stock a Solid Choice Right Now?
ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2023-09-07 08:00:00 - GlobeNewsWire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference.
2023-07-09 06:53:51 - Seeking Alpha
ProQR: Too Many Failures For Its RNA Technology
PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here.
2023-07-06 07:00:00 - GlobeNewsWire
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation at the RNA Editing Summit, July 11-13, 2023 in Boston, MA, USA.
2023-05-16 09:53:36 - Zacks Investment Research
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a year ago.
2023-04-20 08:00:00 - GlobeNewsWire
ProQR Announces Upcoming Investor Conferences in April and May
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced that Company management will participate in the following upcoming investor conferences and events.
2023-03-29 12:30:55 - The Motley Fool
Why Shares of ProQR Therapeutics Dropped on Wednesday
ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022.
2023-03-07 08:00:00 - GlobeNewsWire
ProQR to Present at Upcoming Scientific and Industry Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company's proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences, including the 8th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA Leaders Europe Congress, March 15-16, 2023, in Basel, Switzerland; and the bi-annual RNA Editing Gordon Research Conference (GRC), March 19-24, 2023 in Ventura, CA, U.S.
2022-12-27 13:52:37 - PennyStocks
5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts
Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-12-23 13:32:16 - Zacks Investment Research
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.